Novartis: COPD bronchodilator shows improvement in study
(CercleFinance.com) - Treatment with Novartis' Ultibro Breezhaler improved cardiac function in chronic obstructive pulmonary disease patients with lung hyperinflation, the Swiss drugmaker said on Thursday.
The company said a study that has been published in the Lancet magazine met its primary endpoint, demonstrating that the bronchodilator led to decreased lung hyperinflation and improvements in cardiac function after 14 days.
Lung hyperinflation is common in people with COPD, and has been linked to impaired cardiac function and a worsening of symptoms - especially breathlessness.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The company said a study that has been published in the Lancet magazine met its primary endpoint, demonstrating that the bronchodilator led to decreased lung hyperinflation and improvements in cardiac function after 14 days.
Lung hyperinflation is common in people with COPD, and has been linked to impaired cardiac function and a worsening of symptoms - especially breathlessness.
Copyright (c) 2018 CercleFinance.com. All rights reserved.